Assessing Agilon Health: Insights From 10 Financial Analysts
Portfolio Pulse from Benzinga Insights
Agilon Health (NYSE:AGL) received mixed ratings from 10 financial analysts, with a shift towards more bearish sentiment over the past three months. The average 12-month price target is now $18.3, down from $24.75, with a high estimate of $28.00 and a low of $9.00. Analysts from firms including Truist Securities, JP Morgan, JMP Securities, Deutsche Bank, Benchmark, Wells Fargo, Goldman Sachs, and RBC Capital have adjusted their ratings and price targets. Agilon Health's financial performance shows strong revenue growth but below-average profitability and efficiency metrics.
January 08, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Agilon Health has received mixed analyst ratings with a downward revision in the average price target to $18.3, indicating a bearish sentiment. The company shows strong revenue growth but struggles with profitability and efficiency.
The reduction in the average price target by analysts suggests a bearish outlook for Agilon Health in the short term. The strong revenue growth is a positive sign, but the concerns about profitability and efficiency metrics such as net margin, ROE, and ROA could negatively impact investor sentiment and the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100